<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>

<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">31561542</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1422-0067</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>19</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of molecular sciences</Title>
                <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of 3-Arylquinoxaline Derivatives as Potential Anti-Dengue Virus Agents.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E4786</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20194786</ELocationID>
            <Abstract>
                <AbstractText>We designed and synthesized a series of novel 3-arylquinoxaline derivatives and evaluated their biological activities as potential dengue virus (DENV) replication inhibitors. Among them, [3-(4-methoxyphenyl)quinoxalin-2-yl](phenyl)methanol (<b>19a</b>), [6,7-dichloro-3-(4-methoxyphenyl)quinoxalin-2-yl](phenyl)methanol (<b>20a</b>), and (4-methoxyphenyl)(3-phenylquinoxalin-2-yl)methanone (<b>21b</b>) were found to significantly inhibit the DENV RNA expression in Huh-7-DV-Fluc cells with a potency better than that of ribavirin. Compound <b>19a</b> reduced DENV replication in both viral protein and messenger RNA (mRNA) levels in a dose-dependent manner and exhibited no significant cell cytotoxicity. Notably, compound <b>19a</b> exhibited a half maximal effective concentration (EC<sub>50</sub>) value at 1.29 ± 0.74 μM. We further observed that the inhibitory effect of <b>19a</b> on DENV replication was due to suppression of DENV-induced cyclooxygenase-2 (COX-2) expression. Docking studies also showed that <b>19a</b> caused hydrophobic interactions at the active sites with Arg29, Glu31, Tyr116, Leu138, Pro139, Lys454, Arg455, and Gln529. The calculated lowest binding energy between the <b>19a</b> and COX-2 was -9.10 kcal/mol. In conclusion, compound <b>19a</b> might be a potential lead compound for developing an anti-DENV agent.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tseng</LastName>
                    <ForeName>Chih-Hua</ForeName>
                    <Initials>CH</Initials>
                    <Identifier Source="ORCID">0000-0001-7392-7104</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801, Taiwan. chihhua@kmu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Cheng-Ruei</ForeName>
                    <Initials>CR</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. st88036942017@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Kai-Wei</ForeName>
                    <Initials>KW</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. dadaking1107@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Int J Mol Sci</MedlineTA>
            <NlmUniqueID>101092791</NlmUniqueID>
            <ISSNLinking>1422-0067</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">3-arylquinoxaline</Keyword>
            <Keyword MajorTopicYN="N">cyclooxygenase-2</Keyword>
            <Keyword MajorTopicYN="N">dengue virus</Keyword>
            <Keyword MajorTopicYN="N">ribavirin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31561542</ArticleId>
            <ArticleId IdType="pii">ijms20194786</ArticleId>
            <ArticleId IdType="doi">10.3390/ijms20194786</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
